Cse In News

OP-ED: Who’ll stop the rain?

How India’s water has been epically mismanaged It has rained non-stop all this week in my hometown of Panjim, the pocket-sized capital city of India’s smallest state. Right outside where I live, beside the estuary where the Mandovi river meets the Arabian Sea at Aguada Bay, the landscape is drenched and utterly dreamy: Sky and sea blurring into each other with sublime effect. This, of course, is the magnificent south-west monsoon, the dramatic weather event that plays out in spectacular style from June to September each year. It is the basis of our civilization, the backbone of our food security, and the wellspring of our culture. Here, we are blessed with an average of just over three metres of annual rainfall, and almost all of it will come down from the heavens in this season. But even as every patch of exposed earth explodes green, and innumerable rivulets become charged with rainwater to feed the state’s 11 rivers, there’s the troubling realization that none of it is going to be enough. This is because by the end of the year many parts of Goa will be right back into water shortage. Our situation is already pretty bad, but it’s far more dangerous right across the border in Maharashtra and Karnataka, where many districts have suffered drought conditions for several years. These are all facets of the increasingly grave, interlinked water crisis that threatens the lives and livelihoods of hundreds of millions of South Asians. The immediate problem is not the monsoon itself. As multiple scientists from three countries (led by Steven Clemens of Brown University) describe in “Remote and local drivers of Pleistocene South Asian summer monsoon precipitation: A test for future predictions,” their research article published in Science last month: “South Asian precipitation amount and extreme variability are predicted to increase due to thermodynamic effects of increased 21st century greenhouse gases.” Put more simply, the fact of increased carbon dioxide in the atmosphere will actually result in more and heavier rainfall from the south-west monsoon for the time being, with the caveat that all this increased precipitation will arrive in more intense bursts of extreme weather. We can see that this is already happening: Each rainy season of the past five years has been accompanied by devastating storms that have wrought immense damage in multiple locations (including Goa just weeks ago). But if it isn’t due to diminished rainfall, how is it that India -- and more broadly, South Asia -- still has such an entrenched water crisis? 2021/07/x-90-1626205920318.png Like so many other problems in our part of the world, it’s due almost entirely to incompetence and epic mismanagement by an entire generation of elites that has wilfully destroyed the age-old water-harvesting systems that sustained their forbears, while installing unsustainably short-sighted and rapacious practices that have brought us -- perhaps irredeemably -- to the brink of disaster. This is the story of Mumbai and Bangalore, but also Karachi and Dhaka, and my once-idyllic Panjim as well: Polluted wells, concretized wetlands, paved-over lakes, encroached rivers and streams, and absurdly inadequate drainage. When it rains it floods, but the water table still doesn’t get replenished. All the while, borewells go deeper, buildings rise higher, and urbanization proceeds unstoppably. It’s a regional issue, but it also has to be acknowledged that no country in the world has depleted its groundwater more carelessly than India. The scale of dependence is staggering: Each year the country uses more groundwater than China and the US combined. The results of this overuse are wholly predictable. According to the New Delhi-based Centre for Science and Environment (CSE), nearly 30% of India’s land mass is currently undergoing desertification (defined as “a type of land degradation in which a relatively dry land region becomes increasingly arid, typically losing its bodies of water as well as vegetation and wildlife”). Taken as a whole, the CSE’s predictions are absolutely horrifying: 26 of 29 states are experiencing enough desertification to be worried, and eight of them already have an emergency because between 40% and 70% of their land mass is threatened. These are Rajasthan, Delhi, Himachal Pradesh, Maharashtra, Jharkhand, Nagaland, Tripura, and Goa. Yes, it’s the sorry truth. My famously lush and riparian Goa, with its three metres of rainfall each and every year, still shows up on this list of states that are turning to desert. It’s maddening: We waste more than we use, and both are more than what we receive from the skies. It’s what Creedence Clearwater Revival sang about in 1970: “Long as I remember the rain been coming down / Clouds of mystery pouring confusion on the ground / Good men through the ages trying to find the sun / And I wonder, still I wonder, who’ll stop the rain?” John Fogerty didn’t suggest an answer to his question, but we know who the culprit is.

Panel for conservation of waterbodies in city

New Delhi: The Wetland Authority of Delhi has constituted a technical committee, which will help in conservation of waterbodies. As the land-owning agencies have prepared documents for notifying 368 waterbodies, the technical committee will review their plans and assist them in technical matters. A senior official of the environment department said, “We had received just 23 brief documents in July last year, but the number of documents prepared rose to 368 in July this year. The newly constituted body will review the brief documents, management plans of wetlands prepared by the departments concerned and advise on any technical matter referred by the Wetland Authority of Delhi.” The official added that the process of notification of wetlands will begin after the committee reviews the brief documents of 368 waterbodies. The chief economist at World Resources Institute at Delhi, Madhu Verma, is the chairperson of the committee. The other committee members are from Teri University, Centre for Science and Environment, Water Technology Centre from Indian Agricultural Research Institute, Wetlands International South Asia, member of Prime Minister’s Science, Technology and Innovation Advisory Council (PM-STIAC) and member secretary of Wetland Authority of Delhi. Earlier, TOI had reported that Delhi currently does not have a single notified waterbody. The Union ministry of environment and forest and climate change came out with guidelines last year for implementing Wetlands (Conservation and Management) Rules, 2017. The guidelines stated that for each wetland proposed to be notified, a ‘brief document’ has to be prepared with information like demarcation of wetland boundary for enforcement of regulation.

Submitted Documents To WHO For Covaxin’s Emergency Use Listing: Bharat Biotech

Bharat Biotech said that WHO has begun reviewing its documents and that it expects to receive a green signal from the world health body at the earliest. Hyderabad-based vaccine maker Bharat Biotech on Monday said that it has submitted all documents required for emergency use listing (EUL) of its Covid-19 vaccine Covaxin to the World Health Organization on July 9. The company further said that WHO has begun reviewing its documents and that it expects to receive a green signal from the world health body at the earliest. "All documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to WHO as of 9th July. The review process has now commenced with the expectation that we will receive EUL from WHO at the earliest," Bharat Biotech International Ltd Chairman and MD Krishna Ella said in a tweet posted by the company. At present, the WHO has approved vaccines by Pfizer/BioNTech, Astrazeneca-SK Bio, AstraZeneca EU, Janssen, Moderna and Sinopharm for emergency public use. Last week, during a webinar organised by the Centre for Science and Environment (CSE), WHO chief scientist Soumya Swaminathan said, WHO is reviewing the consolidated data uploaded by Bharat Biotech on the health body’s portal and that it is likely to take a decision regarding Covaxin within four to six weeks. According to WHO guidelines, EUL is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies. "We currently have six vaccines approved with EUL and have recommendations from our Strategic Advisory Group of Experts (SAGE). We continue to look at Covaxin. Bharat Biotech has now started uploading their data on our portal and that is the next vaccine that will be reviewed by our experts committee," Swaminathan had said. At present, there are 105 candidate vaccines in clinical evaluation out of which 27 are in phase three or four, she said. There are another 184 candidate vaccines in preclinical evaluation. Most of the vaccines are designed for a two-dose schedule, she added.

All documents required for emergency use listing of Covaxin submitted to WHO: Bharat Biotech

Bharat Biotech on Monday said that all documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to the World Health Organisation (WHO). The Hyderabad-based firm added that the review process has now commenced "with the expectation that Covaxin will get EUL from WHO at the earliest". The EUL is a license from the WHO to the company to make their vaccine available to people affected by a public health emergency. WHO chief scientist Soumya Swaminathan had on Saturday said that the global health body is likely to take a decision on EUL of Bharat Biotech’s Covid-19 vaccine Covaxin within four to six weeks. Speaking at a webinar organised by the Centre for Science and Environment (CSE) on Friday, Soumya Swaminathan said WHO is reviewing the data for Covaxin being uploaded on the health body's portal by vaccine maker Bharat Biotech. Talking about the process of EUL, Swaninathan said, "There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group." “The completeness of the data, which includes safety and efficacy and also the manufacturing quality, standard is provided. So, I expect that Bharat Biotech has already submitted data and in four to six weeks there will be a decision on its inclusion,” Swaminathan added. Currently, WHO has granted emergency use authorisation to six Covid-19 vaccines - Pfizer-BioNTech jab, Astrazeneca vaccine being manufactured by SK Bio and Serum Institute of India (SII), AstraZeneca EU, Janssen, Moderna, and Sinopharm.

Covid Waste Bazaar: Pandemic medical trash up for sale in Delhi-NCR

Contaminated Covid-19 medical waste is being sold for re-use through scrap yards across Delhi-NCR, an India Today investigation has revealed. Mounds of contamination lie scattered along an open yard dotted with shacks. Impoverished women sort out PPE kits, syringes, fluid bottles, and gloves as their children play nearby. Welcome to the grey market of Covid medical waste hauled from some of Delhi's leading private and government hospitals. An India Today investigation found large junkyards in the national capital region procuring the pandemic trash for re-sale. COVID WASTE FOR RETAIL, WHOLESALE, RECYCLING Along the Delhi-Ghaziabad border at Bhopura, discarded protective gear was being dried under the summer sun on an open compound. When probed, workers and their operators explained that the waste is prepared for local retailers, wholesalers and for recycling units. The yard's manager, who identified himself as Bhandari, confessed that the waste comes in from some of Delhi's prominent hospitals. The labeling stamped on the used PPE kits corroborated his claims. "Our material comes from RML and other hospitals," Bhandari replied, supervising sorting and loading for deliveries. His truck driver disclosed the destination. The Covid scrap, the driver revealed, was headed to a recycling factory at Loni in Ghaziabad. "There's one mill there at Loni, near the roundabout along the canal," he replied when asked about the location to which he was supplying the material. Individual buyers looking for cheap kits and syringes also buy the stuff from the same Bhopura yard by the kilos. When approached, Sunil Kumar, its operator, offered used fluid bottles, syringes and PPE gear in bulk. "How much quantity of PPE kits can you offer?" the reporter asked. "From 400 to 500 kilos," Kumar replied. "You can also get 200-250 kilos of (fluid) bottles." He claimed to be getting Covid medical waste from two private hospitals at Patparganj and Vaishali in Delhi. INDIA UNDER-REPORTING COVID WASTE? India has generated 203 tons of Covid medical waste per day during the pandemic, according to the data issued by the Central Pollution Control Board (CPCB) till May 10, 2021. The quantity makes up almost 20 per cent of the total biomedical trash generated since the outbreak began. But even this hefty percentage might be an under-representation, warns a recent study by the Centre for Science and Environment (CSE). While the Covid-19 caseload has increased by a massive 234 per cent between the first and second waves of the pandemic, Covid-19 biomedical waste generation went up by only eleven per cent. The CPCB attributes this mismatch to better segregation of the waste, but our research points clearly to under-representation," said Atin Biswas, a programme director at the CSE. On its part, the CPCB has already recommended separate arrangements for handling, segregating and disposing of Covid bio-medical waste at designated disposal facilities equipped with incinerators. WASTE ENDING UP AT UNORGANIZED YARDS But a lot of infectious refuse seems to be ending up in unorganized yards, India Today's Special Investigation Team found. "You can check PPE kits, the vests, in the garbage," said Aslam, an operator of a junkyard at Arthala in Ghaziabad, pointing towards a heap of discarded gear. "Where are you getting this material from?" the reporter asked. "From small hospitals," Aslam answered. He then went on to show used syringes and bottles. "We sell this material by weight. This PPE kit is sold at Rs 10 per kilo, the fluid bottles at Rs 57 (per kilo), and syringes at Rs 63 per kilo," Aslam said. The scene was no different at a junkyard in Delhi's Shram Vihar, with women seen sorting Covid waste from the piles of medical trash. "It's medical waste from hospitals," said one of the workers.

All documents submitted to WHO for emergency use listing of Covaxin, says Bharat Biotech

The Hyderabad-based biotechnology firm said the review process has now commenced and it expects to receive EUL from the WHO at the earliest All documents required for Emergency Use Listing (EUL) of Covaxin have been submitted to the World Health Organisation (WHO) as of 9 July, Hyderabad-based Bharat Biotech said today. The biotechnology company also said that the review process has now commenced and it expects to receive EUL from the WHO at the earliest. Recently, WHO chief scientist Soumya Swaminathan said that the global health body is likely to take a call on whether to include Bharat Biotech's Covid-19 vaccine Covaxin in the EUL in the next four to six weeks. At a webinar held by the Centre for Science and Environment (CSE) on Friday, the WHO chief scientist said that the global health body is reviewing Covaxin while its manufacturer Bharat Biotech uploads all the data on the WHO portal. According to WHO guidelines, EUL is a procedure to streamline the process in which new products can be approved and used during public health emergencies like a pandemic. "There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete Phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group," Swaminathan explained. "The completeness of the data, which includes safety and efficacy and also the manufacturing quality and standard, is provided. So, I expect that Bharat Biotech has already submitted data and in four to six weeks there will be a decision on its inclusion," she said. As of now, the WHO has approved Covid-19 vaccines by Pfizer/BioNTech, Astrazeneca-SK Bio/Serum Institute of India, AstraZeneca EU, Janssen, Moderna and Sinopharm for emergency use. "We currently have six vaccines approved with EUL and have recommendations from our Strategic Advisory Group of Experts (SAGE). We continue to look at Covaxin. Bharat Biotech has now started uploading their data on our portal and that is the next vaccine that will be reviewed by our experts' committee," Swaminathan said. At present, there are 105 vaccine candidates under clinical evaluation of which 27 are in the third or fourth phase. Another 184 candidates are in preclinical evaluation. Most coronavirus vaccines are designed with a two-dose schedule.

Coronavirus: India reports 41K+ new cases nearly 900 more dead

India on Sunday reported over 41,000 new COVID-19 cases along with nearly 900 more deaths. Several states have eased COVID-19 restrictions to stem the viral spread in light of the decline in infections, however, government officials warn against letting the guard down. World Health Organisation (WHO) Chief Scientist Soumya Swaminathan has also noted that the coronavirus pandemic isn't slowing down. Here are more details. In this article India's tally reaches 3.08 crore; 4.08 lakh dead Cases dipped after second wave peaked in May 73% new cases concentrated in 5 states Over 38 crore vaccine doses provided to states/UTs: Centre COVAXIN emergency listing likely in 4-6 weeks: WHO Statistics India's tally reaches 3.08 crore; 4.08 lakh dead According to the Union Health Ministry, till Sunday morning, India reported a total of 3,08,37,222 COVID-19 cases . The death toll has reached 4,08,040. So far, 2,99,75,064 patients have recovered, while 4,54,118 cases involve active infections. In the past 24 hours alone, India recorded 41,506 new infections, 41,526 more discharges, and 895 fresh fatalities. 37,60,32,586 vaccine doses have been administered so far. Trend Cases dipped after second wave peaked in May India's second wave peaked on May 7, when 4.14 lakh single-day cases were reported, over four times the number of cases reported during the first wave in mid-September. Although infections have declined since the second wave peaked, India crossed the three crore-mark on June 23. Notably, India had crossed the one crore-mark on December 19, 2020, and the two crore-mark on May 4, 2021. States 73% new cases concentrated in 5 states Maharashtra reported 8,296 new COVID-19 cases along with 6,026 more recoveries. Kerala, the second worst-hit state after Maharashtra, reported 14,087 new cases and 11,867 discharges. Meanwhile, the third worst-hit Karnataka added 2,162 new cases and 2,879 recoveries. Tamil Nadu, the fourth worst-hit state, reported 2,913 new cases and 3,321 recoveries. Andhra Pradesh reported 2,925 new cases and 3,937 recoveries. Vaccinations Over 38 crore vaccine doses provided to states/UTs: Centre The Health Ministry said Sunday that over 38.6 crore COVID-19 vaccine doses have been provided to states/union territories so far, while 11.25 lakh doses are in the pipeline. Over 1.44 crore doses are still available with states/UTs for use, it said. India has managed to fully vaccinate 5.5% of its total population, while over 22% has received at least one dose. COVAXIN COVAXIN emergency listing likely in 4-6 weeks: WHO WHO's Swaminathan also said that the global health body is likely to take a call on whether Bharat Biotech's COVAXIN will be granted emergency use listing (EUL) in the coming four to six weeks. She was speaking at a webinar held by the Centre for Science and Environment (CSE) on Friday. COVAXIN —over 77% effective—is a two-dose inactivated vaccine indigenously produced in India.

India Today Impact: Delhi Health Minister assures action on illegal sale of Covid trash

Delhi Health Minister Satyendar Jain has taken note and assured action against the illegal sale of Covid-19 biomedical waste in the national capital region. After an India Today investigation revealed the illegal sale and re-use of Covid-19 biomedical waste in the national capital region, Delhi Health Minister Satyendar Jain took note and assured action. He said, "If this is happening, then it is absolutely wrong. The responsibility of proper disposal of biomedical waste is that of the Municipal Corporation of Delhi. Keep me informed, I will definitely take action against it." "We will also talk to the Municipal Corporation of Delhi and take action against it," he said. An India Today investigation found large junkyards in the national capital region procuring the pandemic trash for re-sale. Along the Delhi-Ghaziabad border at Bhopura, discarded protective gear was being dried under the summer sun on an open compound. When probed, workers and their operators explained that the waste is prepared for local retailers, wholesalers and for recycling units. India has generated 203 tons of Covid medical waste per day during the pandemic, according to the data issued by the Central Pollution Control Board (CPCB) till May 10, 2021. The quantity makes up almost 20 per cent of the total biomedical trash generated since the outbreak began. But even this hefty percentage might be an under-representation, warns a recent study by the Centre for Science and Environment (CSE). "While the Covid-19 caseload has increased by a massive 234 per cent between the first and second waves of the pandemic, Covid-19 biomedical waste generation went up by only eleven per cent. The CPCB attributes this mismatch to better segregation of the waste, but our research points clearly to under-representation," said Atin Biswas, a programme director at the CSE. On its part, the CPCB has already recommended separate arrangements for handling, segregating and disposing of Covid bio-medical waste at designated disposal facilities equipped with incinerators.

ऑपरेशन कोविड वेस्ट से हरकत में आई दिल्ली सरकार, स्वास्थ्य मंत्री बोले- दोषी बख्शे नहीं जाएंगे

इंडिया टुडे के 'ऑपरेशन कोविड वेस्ट बाज़ार' पर दिल्ली के स्वास्थ्य मंत्री सत्येंद्र जैन ने कार्रवाई का आश्वासन दिया है. आजतक से बात करते हुए स्वास्थ्य मंत्री सत्येंद्र जैन ने कहा कि दोषियों के खिलाफ कार्रवाई करेंगे. इंडिया टुडे के 'ऑपरेशन कोविड वेस्ट बाज़ार' पर दिल्ली के स्वास्थ्य मंत्री सत्येंद्र जैन ने कार्रवाई का आश्वासन दिया है. आजतक से बात करते हुए स्वास्थ्य मंत्री सत्येंद्र जैन ने कहा कि दोषियों के खिलाफ कार्रवाई करेंगे. इंडिया टुडे ने कोविड -19 बायोमेडिकल कचरे की अवैध बिक्री और फिर से इस्तेमाल करने का खुलासा किया था. इस पर दिल्ली के स्वास्थ्य मंत्री सत्येंद्र जैन ने इंडिया टुडे से कहा, 'अगर ऐसा हो रहा है तो बिल्कुल गलत है, बायोमेडिकल वेस्ट को ठीक से निपटारा करने की ज़िम्मेदारी दिल्ली नगर निगम (MCD) की है,  मुझे जानकारी दीजिए, इसके खिलाफ़ ज़रूर कार्रवाई करेंगे, इस मामले में दिल्ली नगर निगम (MCD) से भी बात करेंगे और इसके खिलाफ़ कार्रवाई करेंगे.' इंडिया टुडे के स्टिंग में खुलासा हुआ था कि दिल्ली के बड़े कबाड़खाने फिर से बिक्री के लिए कोविड कचरा खरीद रहे हैं. भोपुरा में दिल्ली-गाजियाबाद बॉर्डर पर सुरक्षात्मक गियर को सुखाया जा रहा था. स्थानीय लोगों ने बताया था कि कचरा स्थानीय खुदरा विक्रेताओं, थोक विक्रेताओं और रीसाइक्लिंग इकाइयों को भेजा जाता है. केंद्रीय प्रदूषण नियंत्रण बोर्ड (सीपीसीबी) द्वारा 10 मई, 2021 तक जारी किए गए आंकड़ों के अनुसार, भारत में महामारी के दौरान प्रतिदिन 203 टन कोविड कचरा निकला है.  सीपीसीबी के आंकड़े बताते हैं कि दिल्ली में प्रति दिन 18.79 टन और उत्तर प्रदेश में प्रति दिन 15.91 टन कचरा निकल रहा था. सेंटर फॉर साइंस एंड एनवायरनमेंट (सीएसई) के मुताबिक, जब महामारी की पहली और दूसरी लहरों के बीच कोरोना केसलोएड में 234 प्रतिशत की भारी वृद्धि हुई है, बावजूद इसके कोरोना बायोमेडिकल अपशिष्ट केवल 11 फीसदी बढ़ा है, इससे कचरे के फिर से इस्तेमाल का शक शुरू हुआ.

Not a weather blip!

Recent heatwaves in Canada and the United States were 'virtually impossible' without human-caused climate change Searing heat, touching 50 degrees Celsius in the otherwise cold regions of Canada and the western regions of the United States, has brought home the message — once again and loudly — that climate change is here and is about to get worse. The heat was so unbearable and off the charts that it killed an estimated 500 people in Canada's British Columbia province. Then there are reports of the savage damage it has done to animals and other creatures. The inferno is now adding to the challenge of wildfires, threatening lives and properties. Europe is seeing a similar heatwave; it is predicted that this year's temperatures will be the highest since records have been kept. Yet another year when we have broken the previous year's heat record! Also Read - A usurpation? The fact is this heatwave is not incidental or accidental — a mere weather blip. Scientists working with the World Weather Attribution initiative conclude that this heatwave "was virtually impossible" without human-caused climate change. They find that the temperatures were so extreme that they lie outside the range of historically observed heat records. They conclude that the frequency of this once-in-a-thousand-year event would increase with temperature rise, and when the world touches 2°C increase over pre-industrial ages, it would become a five- to 10-year event. What then is clear is this: One, climate change is happening faster than expected and we are certainly unprepared. Two, climate change is a great leveller — extreme and variable rain, increased frequency of tropical cyclones and heat and cold are hitting the world's poorest. Each event cripples them and makes them even more vulnerable and marginalised. But the rich are also not excluded from this revenge of nature. The death of people from heatwaves in Canada must keep reminding us of the tragedy that awaits everyone. Also Read - A fillip to growth Even as I write this, perhaps for the umpteenth time (my readers must forgive me), we have still not seen the writing on the wall. Our actions still do not match our words. The technologies to combat climate change are available — but they require application at a disruptive and transformative scale. This is what we are missing. I say this because every extra day of procrastination will make the task even more difficult. Take the case of rising heat. To adapt and survive, the rich in otherwise temperate regions will now invest more in devices like air conditioners to cool their homes. This will, in turn, add to the energy demand and, given that countries are still fiddling around with fossil fuel-based electricity, it will add to greenhouse gas emissions. Also Read - Latent threat We know that heating and cooling devices take up the bulk of the power demand in our cities today. In Delhi, research by my colleagues at the Centre for Science and Environment (CSE) shows as soon as the temperature crosses 27-28°C, the cooling demand increases exponentially — electricity demand rises by 190 MW for every degree rise in mercury. With more electricity generation, there will be more emissions, increasing the temperatures even more. The vicious cycle will spiral out of control. This direct relationship between heat and energy has another dimension to it — thermal comfort or discomfort. This is not just about temperatures but also about how well-designed and ventilated our living spaces are. This is why even when temperatures are not so high, but there is humidity or lack of air, we feel uncomfortable and "hot". The fan makes the air conditioner more efficient as it evaporates moisture from our bodies. It is about cooling but also about design. Just consider how traditional buildings were designed to keep out the heat; by designing for the sun and wind, and not against nature. They used orientation and shades on a window — what we now call passive architecture — to ensure that buildings were protected from glare; they used courtyards and open windows for ventilation. Trees provided shade, as much as other environmental benefits. Sadly, modern architecture built on glass facades and closed spaces for air cooling has shunned and dismissed this knowledge as unnecessary and backward. Then there is also the fact that more heat will add to water stress — for irrigation, for drinking and for fighting forest fires. As we pump more water from the ground or use electricity for transporting water, we will need more energy — further reinforcing the vicious cycle. This is why we must go back to finding ways of optimising local water resources; harvesting the rain where and when it falls so that we can reduce dependence on pumped- and energy-dense water. In the heating planet, this knowledge of living with extreme heat and cold without increasing the energy footprint of our living spaces and cities will be crucial. So, as much as we need to move away from fossil fuels, we need to make sure we can do much more with much less energy — this is the climate change challenge. The scorched world should teach us this. DTE Views expressed are personal

Virus, variant and vaccines

The main worry is the price of vaccines, not production, says Sunita Narain It’s a make-or-break moment for our world. A race is on between the virus and its variants and vaccination. The speed at which the novel coronavirus is mutating means that nobody is safe until everyone is safe. According to the WHO, the world needs some 11 billion doses of vaccines and these need to reach the poorest and the remotest places as quickly as possible. Otherwise, there is a fear that the virus will spread and it will return in a mutated form and make even the protected vulnerable to the new variant. The issue is not the vaccine, or even the ability of the world to manufacture it. As of June 2021, there are over 200 vaccine candidates in the offing — with 102 reaching the stage of clinical trial. The WHO estimates that the world will be able to manufacture some 14 billion doses by the end of 2021. China’s two vaccine makers — Sinopharm and Sinovac — plan to produce around 3 billion doses. US-headquartered Pfizer-BioNTech have ramped up capacity to 3 billion doses as have Oxford-AstraZeneca. And then there are others. So, there is no shortage per se. The problem is related to the cost of the vaccine; it needs to be affordable for a vast number of people in the world. The going price of the vaccine is extremely opaque as companies are seeking profits wherever they can take them. The WHO does not track the price and the only sources are media reports. A review shows the price in general ranges from $2.50 to $20 per dose, with Oxford-AstraZeneca being the cheapest. Interestingly, while the EU paid $2.50 per dose, South Africa was charged $5.25. The vaccine by Sinopharm costs $15 per dose in Sri Lanka and $10 per dose in Bangladesh — in both cases the governments have placed the orders. But there are also reports that Sinopharm is selling its vaccine at $40 per dose in Argentina and that the US price for Moderna is $37. Vaccine companies want to keep the windfall coming. The strategy for ramping up capacity is to either do so themselves — like Pfizer, which has reportedly outsourced its legacy vaccines to other companies and will manufacture the 3 billion doses in-house — or sign contracts with other facilities so that the Covid-19 vaccine supply is ramped up but prices and profits remain intact. In all cases, the companies will control the price. Wherever they have offered discounts, as in the case of Astra-Zeneca in the EU, they say they have done so because the governments have invested in the research and development of the vaccine. But company executives have been quick to say these are “pandemic prices” and they expect the cost to increase manifold next year or the year after. In this situation vaccine inequity is inherent and inevitable. Poor countries cannot afford the vaccine. The Indian government, which has agreed to vaccinate its 1 billion people free of cost, has placed orders for some 440 million doses (of the 2 billion it needs) at Rs 150 per dose ($2) from Serum Institute of India (Covishield) and Bharat Biotech (Covaxin). This will put a burden on India’s economy, already reeling from the pandemic losses. Yet, the country’s universal vaccine programme is within its reach because of the low cost of each dose. There is no way other countries — from Bangladesh to Cameroon — can afford to pay $10-15 per dose to vaccinate their people free of cost. So, the way ahead has two options. One, which Germany and the UK favour, is to buy the vaccine from their companies and supply it to the WHO’s COVAX facility — set up to distribute Covid-19 vaccines worldwide. Boris Johnson, host of the recently concluded G7 Summit, has with much fanfare said his country will donate 100 million surplus vaccines — they bought in excess of their needs — of which it will dispatch 5 million by September 2021. All together with the US contributing another 500 million, the G7 has said it will provide 1 billion doses by mid-2022. This is too little, too late — cases in Africa are already on the rise. There is also no plan on how the world will, in this strategy of buying and donating, be able to afford the cost of universal vaccination. COVAX is already facing shortages and broken promises of supply. This is where the second option of providing a temporary waiver on intellectual property rights (TRIPS) comes in. It will allow other companies to mass produce the vaccine. And, as it happened in case of HIV/AIDS drugs, the price would go down when this waiver is given. The reduced price will allow for increased availability and access. This makes the pandemic response truly global — and the vaccines a global good. But this does mean that the “free world” has to deepen its tryst with democracy. To fight what the US president called “autocracy” in the world, it will need to show how it will reestablish the “public” in the public — currently we have dismembered the state and allowed the market to grow and believed that this will empower societies. This has not. The state-market-consuming society combine has brought things to such a pass. This is what needs to be reinvented. For Covid-19 and beyond.

WHO to take call on emergency use listing of Covaxin in 4 to 6 weeks, says chief scientist

The WHO is likely to take a decision on the inclusion of Bharat Biotech’s Covid-19 vaccine Covaxin in the emergency use list in the next four to six weeks, chief scientist Soumya Swaminathan said on Friday. The World Health Organisation (WHO) is likely to take a call on whether to include Bharat Biotech’s Covid-19 vaccine Covaxin in the emergency use list (EUL) in the next four to six weeks, WHO chief scientist Soumya Swaminathan said. VDO.AI At a webinar held by the Centre for Science and Environment (CSE) on Friday, she said that the global health body is reviewing Covaxin while its manufacturer Bharat Biotech uploads all the data on the WHO portal. As per WHO guidelines, emergency use listing (EUL) is a procedure to streamline the process in which new products can be approved and used during public health emergencies like a pandemic. “There is a process to be followed for EUL and pre-qualification of vaccines under which a company has to complete Phase 3 trials and submit the whole data to the regulatory department of WHO which is examined by an expert advisory group,” Swaminathan explained. “The completeness of the data, which includes safety and efficacy and also the manufacturing quality and standard, is provided. So, I expect that Bharat Biotech has already submitted data and in four to six weeks there will be a decision on its inclusion,” she said. advertisement VACCINES UNDER EVALUATION As of now, the WHO has approved Covid vaccines by Pfizer/BioNTech, Astrazeneca-SK Bio/Serum Institute of India, AstraZeneca EU, Janssen, Moderna and Sinopharm for emergency use. “We currently have six vaccines approved with EUL and have recommendations from our Strategic Advisory Group of Experts (SAGE). We continue to look at Covaxin. Bharat Biotech has now started uploading their data on our portal and that is the next vaccine that will be reviewed by our experts committee,” Soumya Swaminathan said. Currently, there are 105 vaccine candidates under clinical evaluation of which 27 are in the third or fourth phase, she said. Another 184 candidates are in preclinical evaluation. Most vaccines are designed with a two-dose schedule. WHO RESEARCH AND DEVELOPMENT BLUEPRINT She went on to speak of the WHO Research and Development Blueprint created in 2016 after the Ebola outbreak. In the blueprint, a research roadmap for diseases with the potential to become pandemics was laid out. “I want to mention the Research and Development (R&D) Blueprint. I think we need to think about how we can do better in the future in terms of development of not just vaccines but drugs, diagnostics and ensuring equitable access. This blueprint was developed after the Ebola outbreak and essentially it laid out a research roadmap for diseases which have pandemic potential,” she said. advertisement “So, when the roadmap was developed in 2016, it mentioned 'Pathogen X' in it which showed that we were anticipating a pandemic, which is now Covid-19,” she added. Swaminathan explained that the roadmap laid out steps to develop target product profiles. This includes standards for vaccines, diagnostics regulatory standards, trial designs and trial simulators. “This pre-thinking helped because WHO was able to bring together scientists, researchers, academics and companies at the beginning of last year to develop a research roadmap for Covid,” she said. DELTA VARIANT Apart from that, Soumya Swaminathan said that the Delta variant of Covid-19 is very transmissible. “Two complete doses are required for protection against the Delta variant but you can still get the infection and can transmit it. This is why masking and other precautions are important to continue,” she said. BOOSTER DOSE On booster doses, Swaminathan said that right now there is no data to confirm whether a booster dose is required after two doses to protect people. “Science is evolving. At this point we don't have data to indicate that everyone will need a booster. If required, we do not know if it will be needed after one year or two years. But data from follow-up studies of vaccinated people are very encouraging and show that immune responses are lasting up to 8, 10 or even 12 months,” she said. “A few studies that have looked at giving booster dose after six months have shown that it can increase the antibody levels so that they can protect against all variants. What we know is you need a high level of antibodies, whether it's through a booster or the first course. We need more studies to see which vaccines will require a booster and when. It could be possible that a combination of two different vaccines is administered in future but these are all being looked into through research and we have to wait,” she concluded.

Coronavirus: India reports 41K+ new cases; nearly 900 more dead

India on Sunday reported over 41,000 new COVID-19 cases along with nearly 900 more deaths. Several states have eased COVID-19 restrictions to stem the viral spread in light of the decline in infections, however, government officials warn against letting the guard down. World Health Organisation (WHO) Chief Scientist Soumya Swaminathan has also noted that the coronavirus pandemic isn't slowing down. Here are more details. n this article India's tally reaches 3.08 crore; 4.08 lakh dead Cases dipped after second wave peaked in May 73% new cases concentrated in 5 states Over 38 crore vaccine doses provided to states/UTs: Centre COVAXIN emergency listing likely in 4-6 weeks: WHO According to the Union Health Ministry, till Sunday morning, India reported a total of 3,08,37,222 COVID-19 cases. The death toll has reached 4,08,040. So far, 2,99,75,064 patients have recovered, while 4,54,118 cases involve active infections. In the past 24 hours alone, India recorded 41,506 new infections, 41,526 more discharges, and 895 fresh fatalities. 37,60,32,586 vaccine doses have been administered so far. Cases dipped after second wave peaked in May India's second wave peaked on May 7, when 4.14 single-day cases were reported, over four times the number of cases reported during the first wave in mid-September 2020. Although infections have declined since the second wave peaked, India crossed the 3 crore-mark on June 23. Notably, India had crossed the 1 crore-mark on December 19, 2020, and the 2 crore-mark on May 4, 2021. 73% new cases concentrated in 5 states Maharashtra reported 8,296 new COVID-19 cases along with 6,026 more recoveries. Kerala, the second worst-hit state after Maharashtra, reported 14,087 new cases and 11,867 discharges. Meanwhile, the third worst-hit Karnataka added 2,162 new cases and 2,879 recoveries. Tamil Nadu, the fourth worst-hit state, reported 2,913 new cases and 3,321 recoveries. Andhra Pradesh reported 2,925 new cases and 3,937 recoveries. Vaccinations Over 38 crore vaccine doses provided to states/UTs: Centre The Health Ministry said Sunday that over 38.6 crore COVID-19 vaccine doses have been provided to states/union territories so far, while 11.25 lakh doses are in the pipeline. Over 1.44 crore doses are still available with states/UTs for use, it said. India has managed to fully vaccinate 5.5% of its total population, while over 22% has received at least one dose. COVAXIN COVAXIN emergency listing likely in 4-6 weeks: WHO WHO's Swaminathan also said that the global health body is likely to take a call on whether Bharat Biotech's COVAXIN will be granted emergency use listing (EUL) in the coming four to six weeks. She was speaking at a webinar held by the Centre for Science and Environment (CSE) on Friday. COVAXIN—over 77% effective—is a two-dose inactivated vaccine indigenously produced in India.

WHO से 4-6 हफ्तों में Covaxin को मिल सकती है इमरजेंसी इस्तेमाल की मंजूरी, चीफ साइंटिस्ट ने दी अहम जानकारी

Covaxin in WHO: विश्व स्वास्थ्य संगठन ने अभी तक भारत बायोटेक की कोविड-19 वैक्सीन कोवैक्सीन को अपनी आपातकालीन उपयोग सूची में शामिल नहीं किया है. इसपर अब जल्द की फैसला हो सकता है. Covaxin WHO Approval Status: विश्व स्वास्थ्य संगठन (World Health Organisation) आने वाले चार से छह हफ्तों में ये फैसला लेगा कि भारत बायोटेक की कोविड-19 वैक्सीन कोवैक्सीन को इमरजेंसी यूज लिस्ट (ईयूएल) में शामिल किया जाएगा या फिर नहीं. इस बात की जानकारी संगठन की चीफ साइंटिस्ट सौम्या स्वामीनाथन (Soumya Swaminathan) ने दी है. शुक्रवार को सेंटर फॉर साइंस एंड एनवायरनमेंट (सीएसई) ने एक वेबीनार कराया था, जिसमें स्वामीनाथन ने ये जानकारी दी. उन्होंने कहा कि विश्व स्वास्थ्य संगठन कोवैक्सीन की समीक्षा कर रहा है (Covaxin WHO Approval Update). वहीं भारत बायोटेक ने भी डब्ल्यूएचओ के पोर्टल पर सारा डाटा अपलोड कर दिया है. संगठन के दिशा-निर्देशों के अनुसार, आपातकालीन उपयोग सूची यानी ईयूएल उस प्रक्रिया को कारगर बनाने की एक प्रक्रिया है, जिसके तहत नए उत्पादों को महामारी जैसी सार्वजनिक स्वास्थ्य आपात स्थिति के दौरान मंजूरी दी जा सकती है और उसका इस्तेमाल हो सकता है. कैसे मिलती है वैक्सीन को मंजूरी? स्वामीनाथन ने कहा, ‘ईयूएल के लिए एक प्रक्रिया का पालन होता है. जिसके तहत कंपनी को तीन चरण पूरे करने होते हैं और फिर सारा डाटा डब्ल्यूएचओ के रेगुलेटरी डिपार्टमेंट को सौंपना होता है (Covaxin WHO Approval Latest). बाद में फिर विशेषज्ञ सलाहकार समूह इस डाटा का विश्लेषण करता है. डाटा में सुरक्षा, प्रभाविकता, विनिर्माण गुणवत्ता और मानक भी शामिल हैं. इसलिए मुझे उम्मीद है कि भारत बायोटेक ने पहले ही डाटा जमा कर दिया है और चार से छह हफ्ते में इसे शामिल करने पर निर्णय हो जाएगा.’ इन वैक्सीन को मिली है मंजूरी अभी तक डब्ल्यूएचओ ने इमरजेंसी इस्तेमाल के लिए फाइजर-बायोएनटेक, एस्ट्राजेनेका-एसके बायो/सीरम इंस्टीट्यूट ऑफ इंडिया, एस्ट्राजेनेका ईयू, जेनसीन, मॉडर्ना और सिनोफार्म की वैक्सीन को मंजूरी दी है (Covid Vaccines Approved by WHO). सौम्या स्वामीनाथन ने कहा, ‘हम कोवैक्सिन को देख रहे हैं. भारत बायोटेक ने अब अपना डाटा हमारे पोर्टल पर अपलोड करना शुरू कर दिया है और यह अगली वैक्सीन है, जिसकी समीक्षा हमारी विशेषज्ञ समिति करेगी.’ उन्होंने कहा कि वर्तमान में क्लिनिकल इवैलुएशन में 105 वैक्सीन कैंडिडेट हैं, जिनमें से 27 तीसरे या चौथे चरण में हैं.